Wokride-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing the movement of stomach contents into the intestines, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release (SR) formulation ensures a prolonged therapeutic effect, improving patient compliance by reducing dosing frequency. Wokride-D Capsule SR is indicated for patients requiring both prokinetic and acid-suppressive therapy, particularly in cases of symptomatic GERD with delayed gastric emptying or refractory dyspepsia. It should be used under medical supervision, considering contraindications such as hypersensitivity to components, and caution is advised in patients with cardiac arrhythmias or hepatic impairment. Adverse effects may include headache, dry mouth, and abdominal cramps. Proper adherence to prescribed dosage and monitoring is essential to optimize therapeutic outcomes and minimize potential side effects.